Evidence map›Paper›PMID 37758067›Full record

ArticleAntiviral research2023

Enhanced broad spectrum in vitro antiviral efficacy of 3-F-4-MeO-Bn, 3-CN, and 4-CN derivatives of lipid remdesivir nucleoside monophosphate prodrugs.

Rachel E McMillan, Michael K Lo, Xing-Quan Zhang, James R Beadle, Nadejda Valiaeva, Aaron F Garretson, Alex E Clark, Jon E Freshman, Joyce Murphy, Joel M Montgomery and 4 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antiviral research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 9 citations in OpenAlex.

  1. Oral lipid prodrug V2043 (1-Antimicrobial agents and chemotherapy · 2026
    Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Rachel E McMillanDivision of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, School of Medicine, La Jolla, CA, USA; Department of Pathology, University of California San Diego, School of Medicine, La Jolla, CA, USA.
Michael K LoViral Special Pathogens Branch, Centers for Disease Control and Prevention, Department of Health and Human Services, Atlanta, CA, USA.
Xing-Quan ZhangDivision of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, School of Medicine, La Jolla, CA, USA.
James R BeadleDivision of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, School of Medicine, La Jolla, CA, USA.
Nadejda ValiaevaDivision of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, School of Medicine, La Jolla, CA, USA.
Aaron F GarretsonDivision of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, School of Medicine, La Jolla, CA, USA; Department of Pathology, University of California San Diego, School of Medicine, La Jolla, CA, USA.
Alex E ClarkDivision of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, School of Medicine, La Jolla, CA, USA; Department of Pathology, University of California San Diego, School of Medicine, La Jolla, CA, USA.
Jon E FreshmanDivision of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, School of Medicine, La Jolla, CA, USA; Department of Pathology, University of California San Diego, School of Medicine, La Jolla, CA, USA.
Joyce MurphyDivision of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, School of Medicine, La Jolla, CA, USA.
Joel M MontgomeryViral Special Pathogens Branch, Centers for Disease Control and Prevention, Department of Health and Human Services, Atlanta, CA, USA.
Christina F SpiropoulouViral Special Pathogens Branch, Centers for Disease Control and Prevention, Department of Health and Human Services, Atlanta, CA, USA.
Robert T SchooleyDivision of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, School of Medicine, La Jolla, CA, USA.
Karl Y HostetlerDivision of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, School of Medicine, La Jolla, CA, USA.
Aaron F CarlinDivision of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, School of Medicine, La Jolla, CA, USA; Department of Pathology, University of California San Diego, School of Medicine, La Jolla, CA, USA. Electronic address: acarlin@health.ucsd.edu.
University of California San Diego · USCenters for Disease Control and Prevention · US

Funding

Development of Sustained-Release Anti-HIV Nucleoside Phosphonate NanoparticlesR01AI131424 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SCHOOLEY, ROBERT TURNER · 2017 to 2021
$3.8M
Revising Anti-coronavirus Compounds to Enhance Activity and Optimize DeliveryR01AI161348 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Karl Y Hostetler, Robert Turner Schooley · 2021 to 2026
$3.1M
UC San Diego Genetics Training ProgramT32GM145427 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BRUCE A HAMILTON · 2022 to 2026
$2.6M
Deconvolution of pro- and anti-viral responses to Dengue virus and Zika Virus infectionsK08AI130381 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CARLIN, AARON F. · 2019 to 2023
$1.0M
NIAID NIH HHS K08 AI130381NIAID NIH HHS R01 AI131424NIAID NIH HHS R01 AI161348NIGMS NIH HHS T32 GM145427
6 · The paper itself

Abstract

Broad spectrum oral antivirals are urgently needed for the early treatment of many RNA viruses of clinical concern. We previously described the synthesis of 1-O-octadecyl-2-O-benzyl-glycero-3-phospho-RVn (V2043), an orally bioavailable lipid prodrug of remdesivir nucleoside (RVn, GS-441524) with broad spectrum antiviral activity against viruses with pandemic potential. Here we compared the relative activity of V2043 with new RVn lipid prodrugs containing sn-1 alkyl ether or sn-2 glycerol modifications. We found that 3-F-4-MeO-Bn, 3-CN-Bn, and 4-CN-Bn sn-2 glycerol modifications improved antiviral activity compared to V2043 when tested in vitro against clinically important RNA viruses from 5 virus families. These results support the continued development of V2043 and sn-2 glycerol modified RVn lipid prodrugs for the treatment of a broad range of RNA viruses for which there are limited therapies.

Indexed as

Antiviral AgentsProdrugsAdenosine MonophosphateAlanineGlycerolLipidsNitroimidazolesNucleosidesAdenosine MonophosphateAlanineAntiviral AgentsF 4GlycerolLipidsNitroimidazolesNucleosidesProdrugsremdesivirAntiviral agentsBroad spectrum antiviraldengue virusEbola virusFilovirusFlavivirusGS-441524GS-5734Hemorrhagic fever virusesHendra virusHenipavirusHuman coronavirus 229ELipid prodrugsNipah virusParamyxovirusPneumovirusRemdesivirRemdesivir nucleosideRespiratory syncytial virusRespiratory virusesRNA virusV2043Zika virus

Identifiers

PMID37758067
PMCPMC10790242
OpenAlexW4387022640

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.